Trials / Active Not Recruiting
Active Not RecruitingNCT05794139
Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy
A Phase 2, Randomised, Double-blind, Placebo-controlled, 2-way Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of NMD670 in Ambulatory Adults With Type 3 Spinal Muscular Atrophy
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 54 (estimated)
- Sponsor
- NMD Pharma A/S · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of NMD670 in the treatment of ambulatory adults with spinal muscular atrophy type 3
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NMD670 | Tablets |
| DRUG | Placebo | Tablets |
Timeline
- Start date
- 2023-09-21
- Primary completion
- 2026-05-01
- Completion
- 2026-05-01
- First posted
- 2023-04-03
- Last updated
- 2026-04-13
Locations
25 sites across 8 countries: United States, Belgium, Canada, Denmark, Germany, Italy, Netherlands, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05794139. Inclusion in this directory is not an endorsement.